Zenarestat

Zenarestat is a potent and orally active aldose reductase inhibitor. Zenarestat improves diabetic peripheral neuropathy in Zucker diabetic fatty rats[1].

Signaling Pathways >> Metabolic Enzyme/Protease >> Aldose Reductase

Research Areas >> Metabolic Disease

Research Areas >> Neurological Disease

Zenarestat (3.2, 32 mg/kg; p.o.; daily for 8 weeks) inhibits nerve sorbitol accumulation in a dose-dependent manner[1]. Animal Model: Zucker diabetic fatty (ZFD) rats (type 2 diabetes models)[1] Dosage: 3.2, 32 mg/kg Administration: P.o.; daily for 8 weeks Result: At 3.2 mg/kg, zenarestat had no significant effect on the delay in F-wave minimal latency (FML) and the slowing of motor nerve conduction velocity (MNCV), although the sorbitol accumulation in the sciatic nerve was partially inhibited in ZDF rats. At 32 mg/kg zenarestat treatment improved these nerve dysfunctions in ZDF rats, along with a reduction of nerve sorbitol accumulation almost to the level of lean rats.

[1]. Shimoshige Y, et al. The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in Zucker diabetic fatty rats. Metabolism. 2000;49(11):1395-1399.